Evening Chronotype Linked to Cardiovascular Risk - Scorecard - MDSpire

Evening Chronotype Linked to Cardiovascular Risk

Researchers examine the association between evening chronotype and cardiovascular disease risk, identifying Life’s Essential 8 cardiovascular health metrics as a key mediator.

  • By

  • Kathryn Wighton

  • January 26, 2026

  • 3 min

Share

Clinical Scorecard: Evening Chronotype Linked to Cardiovascular Risk

At a Glance

CategoryDetail
ConditionCardiovascular Disease Risk
Key MechanismsAssociation with lower attainment of AHA's Life’s Essential 8 metrics, mediated by nicotine exposure, sleep, blood glucose, body weight, and diet.
Target PopulationAdults aged 39 to 74 years, free of myocardial infarction and stroke.
Care SettingProspective cohort study within the UK Biobank.

Key Highlights

  • Definite evening chronotype linked to a 16% higher risk of cardiovascular disease.
  • 75% of the association mediated by poorer AHA Life’s Essential 8 scores.
  • Participants with evening chronotype had a 79% higher prevalence of unfavorable LE8 scores.

Guideline-Based Recommendations

Diagnosis

  • Assess chronotype using validated self-reported measures.

Management

  • Encourage improvement in AHA Life’s Essential 8 components.

Monitoring & Follow-up

  • Regularly evaluate cardiovascular health metrics.

Risks

  • Consider potential misclassification of chronotype and residual confounding.

Patient & Prescribing Data

322,777 adults from the UK Biobank.

Focus on lifestyle modifications to improve LE8 scores, particularly in those with evening chronotype.

Clinical Best Practices

  • Promote healthy sleep patterns and dietary habits.
  • Address nicotine exposure in patients with evening chronotype.

References

Original Source(s)

Evening Chronotype Linked to Cardiovascular Risk

  • by Kathryn Wighton

  • January 26, 2026

Related Content

Not All Poststroke Cognitive Patterns Plateau

Researchers identify divergent recovery, persistence, and decline patterns across cognitive domains following stroke.

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.